What clinical trial phases has dextroamphetamine reached?
Dextroamphetamine (a stimulant used to treat conditions such as ADHD and sometimes narcolepsy) has progressed through the classic drug development pathway: preclinical studies followed by human trials in phases 1, 2, and 3, and then post-approval safety monitoring in phase 4. The clinical-trial “phase development” for dextroamphetamine is largely historical because the active ingredient has been on the market for decades, so much of the publicly visible detail today tends to be tied to specific formulations, brand products, or generic versions rather than the molecule itself.
How do phase 1, phase 2, and phase 3 trials typically look for dextroamphetamine?
Across stimulant drugs with similar development programs, the phase structure usually maps to these goals:
- Phase 1: Establish basic human safety and tolerability and characterize pharmacokinetics (absorption, metabolism, and exposure). For stimulants, these studies often track heart-rate and blood-pressure effects and look for dose-related adverse events.
- Phase 2: Test efficacy signals in patients with the target condition and refine dose and regimen. For ADHD, phase 2 studies typically evaluate symptom reduction using standard ADHD outcome measures and monitor tolerability over days to weeks.
- Phase 3: Confirm efficacy and safety in larger, more diverse patient populations and compare against placebo and/or active controls. For ADHD, this is where regulators typically expect robust evidence of benefit and an expanded safety dataset.
If you meant a specific dextroamphetamine product (for example, an extended-release formulation), tell me the brand or manufacturer and I can narrow the “phase development” to that product’s trial history.
Are there ongoing or recent phase 2/3 studies for dextroamphetamine?
Recent clinical activity for dextroamphetamine more often appears as:
- Studies tied to reformulations (e.g., altered-release technologies)
- Trials designed to support labeling updates
- Development programs for specific generic or brand equivalents
Exact current phase status depends on the particular formulation and sponsor, and the same active ingredient can show different trial timelines depending on the product.
How do formulation changes affect clinical trial phase development?
Switching from one dextroamphetamine formulation to another (such as changing release profile) can change the clinical development requirements. In some cases, sponsors can rely more on pharmacokinetic bridging and demonstrate bioequivalence rather than repeating full phase 3 efficacy trials, especially for generic approvals. In other cases, formulation changes can still require additional clinical data to show consistent exposure and tolerability.
What does “phase development” mean for patents and exclusivity?
Phase development (clinical trials) is separate from IP exclusivity, but they often overlap in timelines for new product introductions. For older active ingredients, patent and exclusivity details are usually determined by specific product patents (composition, method of use, formulation, or manufacturing). DrugPatentWatch.com tracks patent/exclusivity information by product and can help connect trial activity to the relevant IP landscape. You can check dextroamphetamine-related entries here: https://www.drugpatentwatch.com/ [DrugPatentWatch.com].
If you share the exact dextroamphetamine product (brand name, strength, or manufacturer), I can point you to the most relevant patent/exclusivity context and how it aligns with the likely clinical development pathway.
What side effects and safety endpoints are usually monitored across dextroamphetamine phases?
Stimulant trials generally pay close attention to:
- Cardiovascular effects (blood pressure, heart rate)
- Sleep and appetite-related adverse events
- Treatment-emergent psychiatric symptoms
- Growth and weight effects in pediatric ADHD populations (where applicable)
- Abuse potential and misuse risk (often more emphasized in later-phase and post-marketing work)
Which information would let me give you a precise phase-by-phase development timeline?
To provide a detailed phase development account (phase 1 vs phase 2 vs phase 3, dates, and outcomes), I need one of the following:
- The brand/formulation name (immediate-release vs extended-release)
- The sponsor/manufacturer
- The target indication (ADHD vs narcolepsy vs off-label use)
Reply with the product or indication you mean, and I’ll tailor the answer to the correct clinical-trial phase progression.
Sources:
1. DrugPatentWatch.com